Ondansetron Phares (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondansetron Phares, is a 5-HT3 receptor antagonist presented as a solid oral dosage form for systemic use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery in adult and pediatric patients. GNH USA supplies Ondansetron Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Phares as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Phares is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways.

- Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: helps control nausea during and after radiotherapy. - Post‑operative nausea and vomiting: decreases the incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related hyperemesis gravidarum (off‑label in some regions): may be considered when conventional therapy fails.

Side effects reported with ondansetron are generally mild to moderate and vary with the route of administration.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - QT interval prolongation: may predispose to cardiac arrhythmias. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic enzyme elevation: abnormal liver function tests. - Vision changes: blurred vision or visual disturbances.

When using Ondansetron Phares, consider the following safety measures:

- Cardiac monitoring: patients with known prolonged QT interval or electrolyte disturbances should be monitored. - Drug interactions: review concomitant medications that may affect cardiac rhythm or serotonin levels. - Pregnancy: use only if the potential benefit outweighs the risk; discuss with a healthcare professional. - Breastfeeding: weigh benefits against potential infant exposure; consult a clinician. - Renal/hepatic impairment: dose adjustment may be required; follow prescriber guidance. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Class I anti‑arrhythmic agents (e.g., quinidine, procainamide): increased risk of QT prolongation. - Certain macrolide antibiotics (e.g., erythromycin): additive QT‑prolonging effect. - Serotonergic agents (e.g., tramadol, linezolid): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, fluconazole): may increase ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): potential alteration of metabolism. - Anticholinergic drugs: may reduce the antiemetic efficacy of ondont…